Skip to main content

Biovie Inc.

BIVI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001580149

In the last 90 days, Biovie Inc. insiders filed 5 open-market purchases and 0 sales; 37 institutions reported holding it in 13F filings for Q2 2026, worth $2.86M in total; no superinvestor holds it.

Other share classesBIVIW

Key figures

Market capClose on Nov 17, 2026
$10.7M
Insider buysLast 90 days, $52.0K in total
5
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +2 vs. previous quarter
37
13F valueReported value at the end of Q2 2026
$2.86M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2026
–
No comparable prior period
Net income, FY2026
-$22.1M
No comparable prior period
Free cash flow, FY2026
–
No comparable prior period
Revenue, Q1 FY2027
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
589.1K
Shares sold short
Change
+44.6K
+8.2% vs. previous
Days to cover
3.68
At average daily volume

Superinvestors holding BIVI, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIVI at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)4:30 PM ETNov 133 daysDo Cuong VPresident & CEOPPurchase+2.50K$1.16+$2.91K+15.5%18.6K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayPalumbo Joseph MChief Medical OfficerPPurchase+4.84K$2.16+$10.5K+406.0%6.04K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayChappell Amy SuzonDirectorPPurchase+727$2.16+$1.57KNew position727 after
Aug 28, 2026 (view filing)8:58 PM ETAug 28Same dayKim Joanne WendyChief Financial OfficerPPurchase+2.50K$2.18+$5.45K+265.7%3.44K after
Aug 28, 2026 (view filing)8:57 PM ETAug 271 dayDo Cuong VPresident & CEOPPurchase+15.2K$2.08+$31.6K+1,677.0%16.1K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K––+100.2%9.99K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K–––5.05K afterDerivative
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+10.0K––+2.3%435.9K after
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+5.00K–––5.00K afterDerivative
Dec 6, 2023 (view filing)Dec 15 daysLateGorlin SteveDirectorSSale−75.7K$1.69−$127.9K−62.0%46.4K after

Top 10 13F holders, Q2 2026

See all 37 holders

The largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding BIVI in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Morgan Stanley605,471$1.17M0.00%+530,250+704.9%Added
Diametric Capital, LP256,636$497.9K0.05%−113,364−30.6%Reduced
Renaissance Technologies LLC127,918$248.2K0.00%+60,000+88.3%Added
Citadel Advisors LLC95,952$186.1K0.00%+50,660+111.9%Added
Vanguard Capital Management LLC70,906$137.6K0.00%−13,161−15.7%Reduced
Geode Capital Management, LLC70,752$137.3K0.00%−13,451−16.0%Reduced
Philadelphia Trust Co50,010$97.0K0.01%−25,000−33.3%Reduced
Vanguard Fiduciary Trust Co37,557$72.9K0.00%00.0%Unchanged
Jane Street Group, LLC35,860$69.6K0.00%+13,069+57.3%Added
Prelude Capital Management, LLC32,583$63.2K0.00%−59,480−64.6%Reduced

Holders of 5% or more of BIVI

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Biovie Inc..

Largest holders of BIVI from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Acuitas Group Holdings, LLC13D/A15.80%3.05M shares–Jul 15, 20226 filingsJun 30, 2025SEC
Morgan Stanley13G/A11.90%896.8K shares+3.90 ppfrom 8.00%Aug 7, 20262 filingsAug 7, 2026SEC
Alta Partners LLC13G8.40%687.3K sharesNewAug 19, 20261 filingAug 19, 2026SEC
Do Cuong V13D5.03%399.0K sharesNewMar 25, 20261 filingMar 25, 2026SEC